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Abstract
Invasive meningococcal disease causes over 3500 cases each year in Europe, with particu-
larly high incidence among young children. Among serogroup B meningococci, which
cause most of the cases, high diversity in the outer membrane proteins (OMPs) is observed
in endemic situations; however, comprehensive molecular epidemiological data are avail-
able for the diversity and distribution of the OMPs PorA and FetA and these can be used to
rationally design a vaccine with high coverage of the case isolates. The aim of this study
was to determine whether outer membrane vesicles (OMVs) derived from an isolate with
constitutive FetA expression (MenPF-1 vaccine) could be used to induce antibodies against
both the PorA and FetA antigens. The immunogenicity of various dose levels and number of
doses was evaluated in mice and rabbits, and IgG antibody responses tested against
OMVs and recombinant PorA and FetA proteins. A panel of four isogenic mutants was gen-
erated and used to evaluate the relative ability of the vaccine to induce serum bactericidal
activity (SBA) against FetA and PorA. Sera from mice were tested in SBA against the four
target strains. Results demonstrated that the MenPF-1 OMVs were immunogenic against
PorA and FetA in both animal models. Furthermore, the murine antibodies induced were
bactericidal against isogenic mutant strains, suggesting that antibodies to both PorA and
FetA were functional. The data presented indicate that the MenPF-1 vaccine is a suitable
formulation for presenting PorA and FetA OMPs in order to induce bactericidal antibodies,
and that proceeding to a Phase I clinical trial with this vaccine candidate is justified.
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Introduction
Invasive meningococcal disease is a severe and life-threatening acute bacterial infection, with
highest incidence among children less than 5 years of age [1]. The majority of invasive menin-
gococcal disease in Europe, the Americas and Australasia is caused by Neisseria meningitidis
expressing the serogroup B capsule (MenB) [1], for which no polysaccharide-based vaccine is
available. The sialic acid residues in the MenB capsule are structurally similar to human neu-
ral-cell adhesion molecules, and both poor immunogenicity and concern over generating auto-
immunity prevent further development of a MenB polysaccharide vaccine [2,3]. Vaccine
prevention of MenB disease has focused on the subcapsular antigens as vaccine candidates.
The first-generation vaccines designed to prevent MenB disease are based on detergent
extracted outer membrane vesicles (OMVs) from wildtype epidemic strains and able to prevent
disease caused by homologous strains in all age groups [4]. Such vaccines have been used
against lineage-specific epidemics of MenB disease [5,6,7,8,9], but mainly provide protection
against the lineage responsible for the epidemic through antibodies directed against the variant
of the immunodominant PorA antigen present [10].
To provide broader protection, effective against multiple meningococcal lineages, multiple
variants and preferably several antigens have been targeted. Major challenges are that immuno-
genic epitopes on these antigens are usually highly variable among meningococcal strains, whilst
more conserved antigens are either transiently expressed, poorly immunogenic, or are incapable
of inducing bacterial clearance when tested in in vitro assays [11]. Vaccine development strate-
gies have included using (i) single variants of multiple antigens, for example the 4CMenB vac-
cine (Bexsero1, Novartis, Sienna, Italy) [12]; or (ii) many variants of a single antigen, for
example the proposed NonaMen vaccine (National Institute for Public Health and the Environ-
ment, Bilthoven, The Netherlands) [13]. There are advantages and disadvantages to each
approach. Using a single antigen may limit coverage as protection is unlikely to be induced
against all variants equally [14], and minimal protection will be induced against non-vaccine
variants. With cocktails of multiple antigens, antibodies to less immunogenic or less abundant
antigens may act synergistically to result in bacterial clearance [15,16]; however, PorA is the
immunodominant protein in the meningococcal outer membrane and in comparison the
immune response evoked by other antigens is often inferior. Other proteins which have shown
good immunogenicity may not be expressed at high levels by all strains for example NadA [17].
PorA and FetA (alternatively called FrpB) are two major outer membrane proteins. FetA is an
iron transporter [18]. The crystal structure of FetA shows that the region of antigenic variation is
concentrated into a sub-domain which protrudes above the predicted location of the outer mem-
brane, and hence is accessible to antibody. PorA is a porin protein, likely to have a similar struc-
ture to PorB [19] where hypervariable regions extend from beta strands in the 16-stranded
barrel. Both PorA and FetA are known to be immunogenic: antibodies to both proteins have
been found in convalescent sera [20,21], suggesting that these antigens are also expressed in vivo.
Rational design of a vaccine that covers the majority of MenB disease isolates requires exten-
sive epidemiological data for the chosen vaccine components. Such data are already available
for PorA and FetA [22]. The study of the distribution of PorA and FetA variants within menin-
gococcal populations show them to be structured with hyperinvasive lineages associated with
particular variants of each antigen [23] which are stable for prolonged periods of time [24]. It
was estimated that a combination of variants of PorA and FetA could provide high levels of
coverage against invasive meningococcal disease in Europe [22,25]. The population structuring
fits a model driven and maintained by competition between meningococcal lineages for hosts
and the development of immunity by those hosts [23]. The model suggests that antibodies to
both proteins are involved in natural protection against meningococcal carriage and disease.
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Consequently, the knowledge of the structuring of meningococcal populations can be used
to rationally design a multivalent vaccine. OMVs, have previously been shown to effectively
induce protective antibodies against PorA. However, generating a reliable antibody response
against FetA expressed in OMVs from wildtype strains is potentially more difficult, as FetA
expression is highly inconsistent in vitro due to negative regulation by iron [26,27].
We have developed an OMV vaccine derived from a MenB strain genetically-modified to
constitutively express FetA. Here we investigated whether the MenPF-1 vaccine could induce
serum bactericidal activity (SBA) against both the PorA and FetA proteins simultaneously in a
proof-of-concept mouse model. For this, a panel of meningococcal isogenic mutants was gen-
erated for use as SBA target strains, allowing a delineation of the specificity of the SBA
responses. Immunogenicity in rabbits, following a toxicology study, is also presented as a pre-
requisite to regulatory approval for a Phase I study.
Materials and Methods
Bacterial strains
Bacterial strains used are described in Table 1.
The SMenPF1.2 strain is a modified version of the MenB H44/76 strain (B:15:P1.7,16) with
wild-type expression of PorA and constitutively high expression of FetA as a result of replace-
ment of the native promoter by transformation. SMenPF1.2, was genetically modified whereby
the promoter upstream of the fetA gene was replaced with a modified promoter derived from
sequences upstream of the porA and porB genes (Fig 1), to increase FetA expression and
remove its regulation by iron. Increased expression of FetA in SMenPF1.2 compared to the
wildtype strain was confirmed by Western blot using a FetA polyclonal serum raised to recom-
binant FetA (Fig 2).
Strain 3043 had previously been generated by transformation of strain H44/76 with a plas-
mid pEAT2 which contains the FetA gene interrupted at an EcoO109I site by a kanamycin
resistance cassette to interrupt expression of the FetA protein (S1 Fig) [28].
The genetically-modified N.meningitidis strains SMenPF1.2 and 3043 were used both as
SBA target strains and as parent strains in order to generate two additional isogenic mutants
for use as SBA target strains. To generate the two new mutants (3311 and 3312) with inter-
rupted expression of the full-length PorA protein, strains SMenPF1.2 and 3043 were trans-
formed with plasmid PorAEryF (provided by Ojas Mehta, CCVTM, Oxford, UK), S2 Fig. This
plasmid contains the porA gene interrupted at a BsiWI restriction site with an erythromycin-
resistance cassette sub-cloned from plasmid pER2 [29]. Meningococci were re-suspended from
overnight growth on blood agar (Oxoid, Cambridge, UK) to an OD 650nm of 0.2–0.3 in 1 mL
Mueller Hinton broth (Oxoid) containing 8 mMMgCl2 (Sigma Aldrich, St Louis, Missouri,
USA). Undigested plasmid DNA (1μg) was added and the suspension was incubated at 37°C
with 150 rpm rotational shaking for 4 hours. Cells were collected by centrifugation and plated
on to Mueller Hinton agar (Oxoid) containing 50 μg/mL erythromycin (Sigma Aldrich) to
select for plasmid integration. To verify the functional effect of the genetic modification, whole
cells of the strain panel were tested in dot-blot with a PorA-specific monoclonal antibody
(Anti-P1.16 01/538, NIBSC, Potters Bar, UK) or a FetA-specific mouse antiserum (generated
by immunization of mice with recombinant FetA).
Meningococcal OMV vaccine (MenPF-1)
OMVs were produced from strain SMenPF1.2 by the Norwegian Institute of Public Health
(Oslo, Norway) by extraction with deoxycholate [30]. The OMVs (active ingredient) contained
21.8% PorA protein, 7.7% FetA protein (as determined by scanning densitometry relative to
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total protein content) and 0.03 μg LPS per μg protein (3%, as determined by silver staining
SDS-PAGE gels, using a quantitative L3,7 standard) (Fig 3). The vaccine product MenPF-1 is a
sterile filtered OMV solution, formulated with Al(OH)3 (1:66 ratio of protein:Al(OH)3 (w/w)),
sucrose (25 mg/mL) and water for injection (WFI) in sealed, capped and labeled injection vials
(0.6 mL per vial including 0.1 mL overfill). A final dose vial contained 50 μg OMV protein per
mL.
SDS-PAGE of OMV samples was performed as described previously [31].
Immunization of mice
Animal studies were conducted according to the UK Home Office regulations under licence
number 80/2157 and were approved by the National Institute for Biological Standards and
Control ethics committee. Final adsorbed MenPF-1 vaccine (0.5 mL per vial) was diluted to
the required concentration (2, 5, 10 or 20 μg protein/mL) in 145 mM sodium chloride solution
(Sigma Aldrich) immediately before use. Groups of 10 (adjuvant-only control) or 20 female
NIH/OlaHsd mice (18–22 g, Harlan Laboratories, Blackthorn, UK) were immunized subcuta-
neously with 500 μl of diluted vaccine suspension at 3 week intervals. For a dose response
study, mice were given two doses of 1.0 μg, 2.5 μg, 5.0 μg, or 10.0 μg of total protein per dose. A
concomitant study of the number of doses was conducted whereby mice were given 1, 2, 3 or 4
doses of 2.5 μg OMVs. Bleeds were collected by cardiac puncture under terminal anaesthesia
three weeks after the last dose. Blood was allowed to clot at 4°C for 18 hours. Serum was sepa-
rated by centrifugation at 9600 x g for 10 minutes and stored at -20°C until use. Sera from 20
mice given 2 doses of 10 μg total protein per dose were pooled for use as a standard serum in
immunological assays.
To provide sufficient volume of sera for comparison against all target strains in SBA, sera
from groups of four mice were pooled resulting in five pools per treatment group.
Immunization of rabbits
Rabbit sera used in this study was obtained from a repeated-dose toxicity study of the MenPF-
1 final vaccine (OMVs adsorbed to aluminium hydroxide), performed by Charles River Labo-
ratories (Edinburgh, UK). Briefly, New Zealand White rabbits (12 weeks at start of dosing,
Table 1. Meningococcal strains used in this study.
Strain Genotype PorA expression FetA expression Source
H44/76 porA, fetAWild-type Wild-type Wild-type Norwegian Institute for Public Health
SMenPF1.2 H44/76 fetAp17bp Wild-type Constitutive This study
3043 H44/76 fetA::kan Wild-type Absent [28]
3311 H44/76 fetA::kan porA::ermC Absent Absent This study
3312 H44/76 fetAp17bp porA::ermC Absent Constitutive This study
Expression levels of major outer membrane proteins PorA and FetA are indicated.
doi:10.1371/journal.pone.0140345.t001
Fig 1. Sequence of the modified porA promoter region used to replace the native fetA promoter.
Bases constituting the -10 and -35 regions are highlighted in green. Bases taken from the porB promoter are
highlighted in blue.
doi:10.1371/journal.pone.0140345.g001
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Harlan, UK) were given four doses of vaccine or control over a 9 week period (Days 1, 22, 43
and 64). Rabbits were given either an adjuvant-only control, a single human dose (25 μg of
OMV with Al(OH)3 adjuvant), or a double human dose (2 x 25 μg of OMV with Al(OH)3 adju-
vant). For each immunization, six male and six female animals were used; six animals in each
group were euthanized on day 66 (main study group), while the remaining six animals were
assigned to a “recovery group” and euthanized on day 92 to assess for delayed toxicity. Blood
samples for immunological analysis were taken pretrial (sample 1) and before dosing on days
22 (sample 2), 64 (sample 3) and 92 (sample 4; recovery group). Serum was separated by centri-
fugation at 1500 x g for 10 minutes and stored at -20°C until use.
In addition, a polyclonal rabbit antiserum pool was generated as a reference for assay stan-
dardization. Four female New Zealand White rabbits (14 weeks old, Harlan, UK) were immu-
nized subcutaneously with 25 μg of OMV with Al(OH)3 adjuvant on days 0 and 21. Blood was
collected on day 42. Sera from all four rabbits were pooled to generate the standard serum.
Enzyme-linked immunosorbent assay (ELISA)
To quantify antibodies in animal sera against OMVs, bulk OMVs were diluted to 2 μg/mL in
15 mM sodium carbonate / 35 mM sodium bicarbonate (both Sigma Aldrich) buffer, pH 9.6.
100μl per well was used to coat 96-well flat-bottomed microtitre plates (NUNC, Thermo
Fisher, Massachusetts, USA) overnight at 4°C. Plates were washed with PBS (137 mM Sodium
chloride/2.7 mM potassium chloride/10 mM disodium hydrogen phosphate/1.8 mM potas-
sium dihydrogen phosphate/pH adjusted to 7.4 with hydrochloric acid, all Sigma Aldrich) con-
taining 0.01% (v/v) Tween-20 (Polyethylene glycol sorbitan monolaurate, Sigma Aldrich). All
Fig 2. Verification of FetA expression in wildtype (H44/76) and genetically modified strain
(SMenPF1.2). Analysis by immunoblot (antiserum raised to recombinant FetA variant F3-3) of SDS-PAGE
gel with 10 μg protein (outer membrane protein preparations) per well. BioRad pre-stained SDS broad-range
standards (70kDa standard shown in Lane 1). Lane 2: Purified FetA F3-3. Lane 3: Wildtype H44/76. Lane 4:
Constitutive Strain (SMenPF1.2).
doi:10.1371/journal.pone.0140345.g002
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further dilutions were made in PBS/5% fetal calf serum (Life Technologies, Paisley, UK). All
incubations were for 60 minutes at room temperature, followed by washing of the plates. Plates
were blocked with dilution buffer, and serial dilutions (1:3) of sera or positive control were
added. After incubation, anti-goat anti-mouse or anti-rabbit IgG horseradish peroxidase conju-
gate (Sigma Aldrich) was added at a 1:2000 dilution. To detect the secondary antibody, plates
were incubated for 5 minutes with 100 μl per well tetramethylbenzidine ELISA substrate (Uni-
versal Biologicals, Cambridge, UK). 100 μl per well 1M sulphuric acid (Sigma Aldrich) was
added to stop the reaction. Absorbance at 450 nm was recorded using a Multiskan MS plate
reader (Labsystems, Helsinki, Finland). IgG concentrations (in arbitrary units), compared to
the standard serum pool (either mouse or rabbit), were calculated using CDC ELISA software
(CDC, Atlanta, USA). The standard serum pool was given a value of 10 arbitrary units.
Recombinant PorA and FetA antigens for ELISA were provided by Hema Patel and refolded
from inclusion bodies using protocols described elsewhere [32,33]. ELISAs against recombi-
nant proteins were completed as above, with the following modifications: for coating of plates,
proteins were diluted to 0.5 μg/mL in PBS; for dilution of sera and secondary antibodies PBS/
0.5% (w/v) bovine serum albumin/0.01% (v/v) Tween-20 was used.
Serum bactericidal assays (SBA)
SBA were performed as described previously [34] with the exception of using Gey’s balanced
salt solution (rabbit complement SBAs) or Hanks balanced salt solution with magnesium and
Fig 3. Characterisation by SDS-PAGE of the MenPF1 outer membrane vesicles used for
immunization. Lanes: 1) Molecular weight protein markers. 2) OMVs from strain SMenPF1.2.
doi:10.1371/journal.pone.0140345.g003
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calcium (HBSS, for human complement SBAs,) with 0.5% (w/v) BSA (both Sigma Aldrich) as
the bactericidal buffer. Sera were tested from a final dilution (after the addition of meningo-
cocci and complement) of 1:4 (human complement) or 1:8 (rabbit complement) with two-fold
serial dilutions to 1:1024 or 1:2048, respectively, with higher dilutions tested where necessary.
Baby rabbit serum was used as an exogenous source of complement (Pel-Freeze Biologicals,
Arkansas, USA). For human complement SBAs, two human donors were identified as suitable
sources. Sera from donor 345, donations 2 and 3 were used for meningococcal strains 3312 and
3043 respectively. Sera from donor 352, donations 2 and 3 were used for meningococcal strain
SMenPF1.2 and 3311 respectively. All complement sources were used at a final concentration
of 25%. The SBA titre assigned was the reciprocal of the serum dilution that resulted in 50%
killing compared to the viable count (or the midpoint between two dilutions if 50% killing was
determined to be between the two dilutions). Sera were assigned a titre of 2 where 50% killing
was not achieved at a dilution of 1:4.
Statistical analysis
Statistical analysis of ELISA data was performed using SPSS software (Version 20, International
Business Machines Corp, New York, USA). Minitab 17 (Minitab. Inc, State College, PA, USA)
was used for the analysis of SBA log transformed titres by fitting general linear models with
meningococcal strains, dose levels or number of doses as factors, with post-hoc Tukey’s or
Dunnett’s tests (using SMenPF1.2 as a control group to compare against 3043 and H44/76)
used where appropriate.
Results
Generation of meningococcal isogenic mutants for vaccine evaluation
As the aim of this study was to determine whether OMVs produced from the modified strain
could be used to induce antibodies against both the PorA and FetA antigens, a total of four
strains was developed in which expression of the two antigens was present or absent, in various
combinations (Table 1). The OMV production strain, strain SMenPF1.2, expressed PorA at
wild-type levels and FetA constitutively at increased levels compared to the repressed wildtype.
An isogenic H44/76 mutant, strain 3043, in which expression of FetA had been interrupted
was also available [28]. Strain SMenPF1.2 was further modified by interruption of the porA
gene to produce strain 3312, in which FetA was expressed constitutively in the absence of PorA
expression. Similarly, the porA gene was interrupted in strain 3043, resulting in strain 3311, in
which expression of both FetA and PorA were absent (Table 1). These strains showed minimal
differences in growth and expression of other proteins compared to wildtype H44/76 (Fig 4).
Expression of PorA and FetA was confirmed in the vaccine strain by dot blot with specific
PorA anti-serosubtype P1.16 monoclonal antibody and a polyclonal antibody raised against
FetA variant F3-3 (data not shown).
Immunogenicity of OMVs in mice
The immunogenicity of the SMenPF1.2 OMVs was investigated in mice using multiple dose
levels. Mice were given two doses of 1 μg, 2.5 μg, 5 μg, or 10 μg of total protein per dose. ELISA
analysis showed an increase in levels of total IgG against the bulk OMVs, PorA and FetA (Fig
5A). Dose responses to both PorA and FetA were observed, although the responses to FetA
were low: for all antigens the concentration of IgG measured in sera from mice given 10 μg pro-
tein per dose was significantly higher than from mice given 1 μg protein per dose (Bulk OMV
Outer Membrane Vesicle Vaccine with Constitutive FetA Expression
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P< 0.001; PorA P< 0.001; FetA P< 0.001). No antibodies were observed in sera from mice
given an adjuvant-only control.
The functional activity of the antibodies was analyzed using SBA assays performed against
panel of four isogenic target strains. SBAs or titres determined using rabbit or human comple-
ment sources are referred to in the text as rSBA or hSBA, respectively. Interaction between
strain and either dose levels or number of doses was not significant for all statistical analyses.
High levels of bactericidal activity using rabbit or human complement, against the strain
used to produce the OMV vaccine were demonstrated at all dose levels tested (Tables 2 and 3).
Similar bactericidal antibody titres were measured against strain 3043 (fetA::kan) as the target,
but titres to both these strains expressing PorA were significantly higher against the porA::
ermC strains 3311 and 3312. Using a human source of complement in the SBA, GMTs against
the modified vaccine strain SMenPF1.2 were significantly higher than those obtained against
the wildtype, unmodified strain H44/76, P< 0.001 (Table 3).
Fig 4. SDS-PAGE of outer membrane proteins from the isogenic mutant strains used to evaluate the
serum bactericidal response. 50 μg total protein was loaded per lane. Lanes: 1) SMenPF1.2 (fetAp17bp), 2)
3043 (fetA::kan), 3) 3311 (fetA::kan porA::ermC), 4) 3312 (fetAp17bp porA::ermC).
doi:10.1371/journal.pone.0140345.g004
Outer Membrane Vesicle Vaccine with Constitutive FetA Expression
PLOS ONE | DOI:10.1371/journal.pone.0140345 October 14, 2015 8 / 17
GMTs for hSBA against strains expressing PorA were significantly higher with 5 or 10 μg
doses, than with the 1 μg dose group, P< 0.05 (Table 3). This dose effect, was also observed
when rabbit sera was used as a source of complement (P = 0.037), although no significant dif-
ferences between any pair of doses was found after Tukey’s multiple comparison test was
applied.
Against strain 3312 (porA::ermC), SBA titres were low in all groups, but overall, across all
dose levels, rSBA titres were significantly higher than against the corresponding strain 3311
which also lacked expression of FetA (P = 0.007). This difference was not observed with a
human source of complement. The highest rSBA titres against 3312 were in sera from mice
given 2.5 μg protein per dose (GMT = 25), but overall, in the porA::ermC there was no signifi-
cant dose effect (P = 0.071).
Fig 5. Immunogenicity of MenPF-1 vaccine in mice. Total IgG titres, calculated in comparison to a pooled
standard serum, were determined for sera from individual mice against bulk OMVs and the PorA and FetA
antigens. The standard serum was given an arbitrary value of 10 units. The geometric mean IgG titres are
indicated with a line. Error bars show the 95% confidence intervals of the mean. (A) Mice given two doses of
four dose levels or an μg protein per doses. Note that the data frommice given two doses of 2.5 μg protein
per dose is included in both figures for comparison, as the immunizations were performed concomitantly.
Actual figures for the data presented are given in S1 Table.
doi:10.1371/journal.pone.0140345.g005
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The mean SBA titre measured against the fetA::kan/porA::ermC strain 3311 was highest for
the 10.0 μg dose (rSBA) or 5.0 μg dose (hSBA). Overall, the contribution to bactericidal killing
by antigens other than PorA and FetA was negligible.
Mice were also immunized with varying numbers of doses: 1, 2, 3 or 4 doses of 2.5 μg pro-
tein per dose. Antibody titres against OMVs, PorA and FetA were low following a single dose
(Fig 5B). Although sera from all mice showed measurable responses to the total OMVs, 5/20
mice that received only one dose showed no measurable IgG to either PorA or FetA. Antibody
GMTs were similar following 2, 3 or 4 doses. IgG titres against FetA were low regardless of the
number of doses administered.
Across all dose numbers, bactericidal activity against strains that did not express PorA
(3311 and 3312) was significantly lower in comparison to SMenPF1.2 and 3043. The bacteri-
cidal activity of sera against strains expressing PorA (SMenPF1.2 and 3043) was significantly
lower following one dose of vaccine compared to multiple doses, rSBA and hSBA: P< 0.05
(Tables 4 and 5). However, the dose effect was more apparent on rSBA titres measured against
PorA-negative target strains; following 4 doses, titres were significantly higher than following
1, 2 or 3 doses, rSBA: P< 0.05 (Table 4).
Overall for all numbers of doses, in the PorA-negative background rSBA titres were signifi-
cantly higher when FetA was constitutively expressed (strain 3312) than against 3311 (fetA::
Table 2. Immunogenicity (rSBA) of MenPF-1 vaccine in mice (dose levels 1.0–10.0 μg per dose).
Dose Serum Bactericidal Titre (GMT) rabbit complement
μg, (2 doses) SMenPF1.2 fetAp17bp 3043 fetA::kan 3312 fetAp17bp, porA::ermC 3311 fetA::kan, porA::ermC
1.0 1383 (921–2078) 1233 (817–1862) 10 (5–19) 5 (4–6)
2.5 2097 (1415–3107) 795 (341–1854) 25 (14–43) 7 (5–10)
5.0 2767 (1982–3862) 3566 (2942–4322) 12 (10–14) 11 (6–17)
10.0 1933 (1197–3123) 1723 (1252–2372) 16 (12–22) 13 (9–19)
Serum bactericidal titres of sera (pools of four mice, ﬁve pools per group) were determined against four target strains using rabbit sera as the complement
source. The table shows geometric mean titres, with the 95% conﬁdence intervals of the mean in parentheses. Mice were given two doses of four dose
levels or an adjuvant only control. Note that the data from mice given two doses of 2.5 μg protein per dose is included in Table 4 for comparison, as the
immunizations were performed concomitantly.
doi:10.1371/journal.pone.0140345.t002
Table 3. Immunogenicity (hSBA) of MenPF-1 vaccine in mice (dose levels 1.0–10.0 μg per dose).
Dose Serum Bactericidal Titre (GMT) human complement
μg, (2 doses) SMenPF1.2 fetAp17bp H44/76 (WT) 3043 fetA::kan 3312 fetAp17bp, porA::ermC 3311
fetA::kan,
porA::
ermC
1.0 117 (38–816) 31 (4–257) 117 (19–735) 4 (1–10) 2 (2–2)
2.5 407 (140–1181) 82 (5–1339) 334 (81–1375) 3 (1–7) 2 (2–3)
5.0 1164 (436–3106) 110 (12–1023) 831 (388–1777) 6 (1–29) 5 (1–19)
10.0 1073 (410–2811) 334 (163–787) 882 (246–3162) 4 (1–16) 3 (2–4)
Serum bactericidal titres of sera (pools of four mice, ﬁve pools per group) were determined against four target strains using human sera as the
complement source. The table shows geometric mean titres, with the 95% conﬁdence intervals of the mean in parentheses. Mice were given two doses of
four dose levels or an adjuvant only control. Note that the data from mice given two doses of 2.5 μg protein per dose is included in Table 5 for comparison,
as the immunizations were performed concomitantly.
doi:10.1371/journal.pone.0140345.t003
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kan), P< 0.001), (Table 4). This strain effect between strains 3312 and 3311 was not replicated
when human complement was used in the SBA. For all dose numbers, there was a significant
strain effect. Where rabbit complement was used, SBA GMTs were significantly higher against
SMenPF1.2 than against the FetA-negative strain 3043; P< 0.05. However after correcting for
multiple comparisons using Dunnett’s test, hSBA titres against SMenPF1.2 were not signifi-
cantly different to those for strain 3043.
Bactericidal titres against the vaccine strain, SMenPF1.2, were compared to the wildtype,
unmodified strain H44/76 that expressed a lower level of FetA. Geometric mean hSBA titres
were higher against the vaccine strain than unmodified H44/76 for all numbers of doses tested,
P< 0.05 (Table 5).
Immunogenicity in rabbits
Sera from the rabbits used in a previous toxicology study (as described in section 2.4 Immuni-
zation of rabbits) were assessed for antibody production by ELISA against bulk OMVs, PorA
and FetA. Three (main group) or four (recovery group) serum samples were available from
each rabbit. The levels of total IgG increased between doses 1 and 3 for all antigens but titres
were similar or lower following 4 doses compared to 3 doses (Fig 6). IgG responses were signifi-
cantly higher in rabbits given 25 μg OMV or 50 μg OMV than those given the adjuvant-only
control (Bulk OMV P< 0.001, PorA P< 0.001, FetA P< 0.001, α = 0.025); however, there
was no significant difference between the 25 μg and 50 μg treatment groups (OMV P = 0.840,
PorA P = 0.262, FetA P = 0.704, α = 0.025).
Table 4. Immunogenicity (rSBA) of MenPF-1 vaccine in mice (number of doses).
Number of doses Serum Bactericidal Titre (GMT) rabbit complement
2.5 μg /dose SMenPF1.2 fetAp17bp 3043 fetA::kan 3312 fetAp17bp,porA::ermC 3311 fetA::kan, porA::ermC
1 253 (200–321) 32 (19–54) 11 (9–13) 6 (5–8)
2 2097 (1415–3107) 795 (341–1854) 25 (14–43) 7 (5–10)
3 1683 (996–2844) 1204 (748–1939) 22 (15–31) 11 (7–16)
4 3366 (2458–4610) 1552 (950–2535) 97 (61–155) 25 (16–38)
Serum bactericidal titres of sera (pools of four mice, ﬁve pools per group) were determined against four target strains using rabbit sera as the complement
source. The table shows geometric mean titres, with the 95% conﬁdence intervals of the mean in parentheses. Mice were given 1, 2, 3 or 4 doses of
2.5 μg protein per dose. Note that the data from mice given two doses of 2.5 μg protein per dose is included in Table 2 for comparison, as the
immunizations were performed concomitantly.
doi:10.1371/journal.pone.0140345.t004
Table 5. Immunogenicity (hSBA) of MenPF-1 vaccine in mice (number of doses).
Number of doses Serum Bactericidal Titre (GMT) human complement
2.5 μg /dose SMenPF1.2 fetAp17bp H44/76 (WT) 3043 fetA::kan 3312 fetAp17bp, porA::ermC 3311 fetA::kan, porA::ermC
1 36 (6–217) 5 (0–46) 14 (4–17) 2 (1–5) 3 (2–5)
2 407 (140–1181) 82 (5–1339) 334 (81–1375) 3 (1–7) 2 (2–3)
3 507 (235–1094) 142 (24–857) 334 (93–1198) 2 (2–2) 2 (2–3)
4 507 (190–1352) 407 (156–1061) 221 (107–453) 2 (1–5) 2 (2–3)
Serum bactericidal titres of sera (pools of four mice, ﬁve pools per group) were determined against four target strains using human sera as the
complement source. The table shows geometric mean titres, with the 95% conﬁdence intervals of the mean in parentheses. Mice were given 1, 2, 3 or 4
doses of 2.5 μg protein per dose. Note that the data from mice given two doses of 2.5 μg protein per dose is included in Table 3 for comparison, as the
immunizations were performed concomitantly.
doi:10.1371/journal.pone.0140345.t005
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Immunogenicity in rabbits against both the PorA and FetA antigens was demonstrated
satisfactorily.
Discussion
Assessment of vaccines against highly variable surface antigens using approaches such as
serum bactericidal assays (SBAs) requires appropriate controls, ideally highly related isogenic
strains that differ only in the vaccine antigens under investigation. Such panels of strains are
invaluable, not only in pre-clinical laboratory studies but also in clinical trials in humans. A
genetically modified meningococcal strain, which constitutively expressed FetA, was used to
produce an OMV for a proof of concept vaccine study along with isogenic strains differing in
their ability to express PorA and FetA. The increased expression of FetA resulted in significant
enhancement of functional antibody responses, compared to that of the wildtype strain H44/
76, indicating that an approach to vaccination using an OMV containing a strong FetA pro-
moter might improve protection. A future development of this concept could be a vaccine con-
taining several additional OMVs each expressing a different PorA and FetA variant to provide
comprehensive coverage against hyperinvasive meningococcal serogroup B disease.
PorA is known to be highly immunogenic in outer membrane vesicles, and is immunodomi-
nant in all other OMV vaccines. Furthermore, where OMV vaccines have been used against
epidemics of meningococcal disease, the protection induced against PorA, as measured by
SBA, was later found to have correlated with protection against disease [35]. It has since been
agreed by consensus that SBA titres against any protein antigens can be accepted as a correlate
Fig 6. Immunogenicity of strain MenPF-1 in rabbits. Total IgG titres calculated in comparison to a pooled standard serum, were determined for sera from
individual rabbits against bulk OMVs and the PorA P1.7,16 and FetA F3-3 antigens. The standard serum was given an arbitrary value of 10 units. Rabbits
were immunized with four doses of either adjuvant alone (Control), 25 μg total protein per doses, or 50 μg total protein per doses. Blood samples were
collected from all animals (n = 12) pretrial (Sample 1), and before dosing on days 22 (Sample 2, post one dose) and 64 (Sample 3, post three doses). A fourth
blood sample was taken from six rabbits on day 92 (Sample 4, post four doses). The graph shows geometric mean units. Error bars indicate the 95%
confidence intervals of the mean. Actual figures for the data presented are given in S2 Table.
doi:10.1371/journal.pone.0140345.g006
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of protection for licensure purposes [36]; however, validation of the SBA as a correlate of pro-
tection for proteins other than PorA can only be gathered after widespread use of a vaccine
based on alternative antigens [37]. This is due to the requirement for a minimum antigen den-
sity on the surface of the bacteria for complement-mediated killing. While PorA is expressed at
high levels by the majority of meningococcal isolates under most growth conditions, the
expression levels of other protein in vivo is unknown and often regulated by nutrient
availability.
Although available data suggests that FetA is involved in natural immunity generated after
invasive disease and during carriage, it is not known whether the level of expression of this
antigen in vivo is sufficient for complement-mediated killing by specific antibodies. Indeed, the
function of FetA remains something of an enigma; unusually for a TonB-coupled iron trans-
porter, it binds iron directly, rather than as part of a siderophore complex [18]. N.meningitidis
is not known to secrete siderophores, and has multiple uptake systems for iron, in the form of
transferrin, and lactoferrin-binding proteins, and heme transporters.
Due to the growth of meningococci on iron-replete media, bactericidal antibodies to this
protein may not be measured in a typical SBA [38]. FetA-specific antibodies have been shown
to be induced following immunization with the New Zealand epidemic OMV vaccine MeNZB
(Chiron Vaccines) [39], although these were not shown to be functional. Expression of FetA in
MeNZB is also known to have varied among batches [27], so the protection that might have
been added by this antigen would have been inconsistent.
In mice, OMVs containing upregulated FetA expressed from a plasmid and lacking PorA
have been shown to induce high levels of FetA-specific, bactericidal antibodies [40]. In the
present study, in mice, OMVs expressing both PorA and FetA induced high concentrations of
antibodies largely directed against PorA. FetA-specific antibodies were also induced, the con-
centration of which was greatest following four, 2.5 ug doses of vaccine. However, in compari-
son to the PorA antibodies the concentration of these was low.
The bactericidal activity of the antibodies was determined by SBA against a panel of isogenic
strains containing both, one, or none of the two antigens. These showed that the bactericidal
killing of the OMV production strain was predominantly dependent on antibodies against
PorA and that the antibodies targeting FetA had more limited bactericidal activity. Although
the difference in rSBA titres for SMenPF1.2 and 3043 achieved significance across dose num-
bers, there was no difference in hSBA titres for dose level or dose number data. This is likely
due to a lower concentration of antibodies induced against FetA, consistent with the strong
immunodominance of PorA. Immunodominance of the response directed to PorA may satu-
rate any differences in bactericidal killing due to levels of FetA expression. This is supported by
data obtained in a background of no PorA expression, where the contribution of FetA to bacte-
ricidal killing (rSBA) was more apparent with higher levels of bactericidal killing when FetA
was expressed (3312) compared to when PorA and FetA were both absent (3311).
There was a positive relationship between the number of doses of vaccine administered and
bactericidal activity. This was observable when either human or rabbit complement was used
in the assay and in target strains where PorA was present or absent. In addition, increased
hSBA titres were associated with higher dose levels in strains expressing PorA. Also noteworthy
was killing directed against antigens other than PorA and FetA increased with number of
doses, as has been found previously in humans [10].
Given the increased sensitivity of baby rabbit complement to induce bactericidal killing,
decreased bactericidal titres were expected when using a human source of complement. The
outcome was particularly low hSBA titres for meningococcal strains where PorA was not
expressed. However, the analysis was based on a limited number of data points (5 pools of sera
per group) and therefore statistical power was limited, particularly after the application of
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post-hoc tests. Moreover, as mentioned earlier it would be difficult to detect subtle differences
resulting from the differing levels of FetA expression when the bactericidal response directed
to PorA is so immunodominant. Additionally, there was no effect of dose level on rSBA titres
for any of the strains tested. This, together with only seeing a positive effect on titres with
greater than 3 doses, would therefore suggest that an optimum dose or schedule may not have
been achieved in these particular pre-clinical experiments.
As many other factors are also likely to be important in determining the immunogenicity of
the antigens within the OMVs, however, such OMVs should be further tested in humans to
compare to these animal models. Although the data show that the vaccine induces FetA-spe-
cific bactericidal antibodies, as isogenic mutant strains with constitutively high FetA expression
were used for immunological analysis, the conclusions cannot be extrapolated to protection
against disease without further evaluation using wildtype meningococci. However, to reliably
evaluate the effect of anti-FetA antibodies against wildtype meningococci the classic iron-
replete SBA growth conditions would likely have to be modified to enable FetA expression.
These modifications would likely affect sensitivity to bactericidal killing in other ways, and as
such would also have to be carefully tested.
The induction of protective humoral immunity against the PorA protein using OMVs is
widely accepted, and humans are known to generate antibodies against FetA following infec-
tion [21]. Here, we have shown that OMVs produced from a meningococcal strain genetically
modified to contain constitutive FetA expression induce bactericidal antibodies against both
PorA and FetA; however in the case of FetA the bactericidal activity was only detectable when
rabbit complement was used. These data indicate that further investigation to determine the
potential immunogenicity in humans of a vaccine based on SMenPF1.2 is worthwhile.
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